Open AccessSafety of Intradialytic Bamlanivimab/Etesevimab Administration in Two COVID-19 Dialysis Outpatients
Author(s) -
Lorenzo Gasperoni,
Chiara Abenavoli,
Gabriele Donati,
Anna Scrivo,
Fulvia Zappulo,
Alessandra Cingolani,
Lilio Hu,
Gaetano La Manna
Publication year - 2022
Publication title -
blood purification
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 57
eISSN - 1421-9735
pISSN - 0253-5068
DOI - 10.1159/000521637
Subject(s) - medicine , hemodialysis , dialysis , end stage renal disease , disease , kidney disease , adverse effect , covid-19 , intensive care medicine , infectious disease (medical specialty)
Chronic hemodialysis patients are at high risk of severe COVID-19 disease and death related to the infection. Anti-spike monoclonal antibodies administration reduces risk of disease progression and hospitalization in high-risk subjects but no clear data on end-stage renal disease are available. We report 2 cases of Bamlanivimab/Etesevimab administration to two not hospitalized chronic hemodialysis patients with SARS-CoV2 infection. Since they are large molecules (human immunoglobulin G1) with molecular weight of 146,000 Da, administration was conducted during the second hour of the dialysis session with no adverse reaction. Conclusions: Intradialytic administration of Bamlanivimab/Etesevimab could be considered safe and may allow adequate clinical observation time without hospital-stay prolongation.